ReachMD

09/03/2025

What’s shifting in the treatment paradigm for obstructive hypertrophic cardiomyopathy (oHCM)?

In this short video, Dr. García-Pavía explores recent clinical findings that raise important considerations for symptom relief, safety, and the potential future direction of oHCM care. Start learning now: https://ow.ly/iMFI50WQKBu

This concise video highlights new findings from the MAPLE-HCM trial in patients with obstructive hypertrophic cardiomyopathy (oHCM). Aficamten...

09/03/2025

DUPLEX reinforces the clinical promise of sparsentan in FSGS.

Compared to irbesartan, patients achieved higher rates of both partial and complete proteinuria remission: 42% vs 26% at 36 weeks, and 18.5% vs 7.5% at any time. eGFR remained more stable over time, with no new safety concerns.

This data supports sparsentan as a potential disease-modifying option in a real-world FSGS population.

Get the full clinical context in this CME episode on patient-centered care: https://ow.ly/ioL450WQrqr

Focal segmental glomerulosclerosis (FSGS) is a prominent cause of kidney failure globally, necessitating dialysis for patient survival as the...

09/03/2025

With ongoing trial data now coming forward, the discussion around obicetrapib and its role in lipid management is shifting in meaningful ways. This conversation underscores the importance of reexamining familiar pathways through the lens of emerging evidence. If you’re interested in how obicetrapib may be positioned within evolving treatment strategies, this is a great time to explore the details.

Learn more about the latest findings: https://ow.ly/RGnC50WQK4v

Dr. Ray reviews pooled data from the BROADWAY and BROOKLYN trials, showing obicetrapib’s consistent LDL-c lowering across a spectrum of background therapies.

09/02/2025

We’re less than three weeks out from !

On September 20, join us in NYC for a one-day, in-person experience focused on the conditions that impact your patients most—sleep apnea, , , migraine, and more.

If you haven’t registered yet, now’s the time: https://ow.ly/fMSj50WPSaO

Join our esteemed chairs, Barbara Dehn, NP, and Anita Nelson, MD, and connect with fellow healthcare professionals for a dynamic, interactive, and evidence-based learning experience that extends beyond the annual visit. Why Attend WHAV 2025? ✅ Learn From Experts – Engage with world-renowned spea...

08/27/2025

DUPLEX showed that proteinuria reduction is not just achievable—it’s meaningful. PARASOL builds on that, aiming to validate proteinuria reduction as a trial endpoint and accelerate therapy development.

Hear more in this discussion between Drs. Howard Trachtman from the University of Michigan and Kenneth Lieberman from Hackensack Meridian Health: https://ow.ly/ySm250WEz7X

Focal segmental glomerulosclerosis (FSGS) is a prominent cause of kidney failure globally, necessitating dialysis for patient survival as the...

08/22/2025

Only 1 month to go until !

On September 20 in NYC, Omnia Education will bring together leaders in OB/GYN, primary care, and advanced practice for a highly focused, in-person learning experience—designed to translate evidence into better outcomes for women.

This year’s agenda includes:

- Underdiagnosed chronic conditions in women
- Sleep health and obstructive sleep apnea across life stages
- Migraine care tailored to women’s hormonal transitions
- Endometriosis: early diagnosis, equitable care, and GnRH antagonists
- IBS: diagnostic tools and satisfaction drivers in women

Plus, you’ll gain access to expert-led discussions, digital content, and multidisciplinary tools you can apply immediately in your practice.

View the full agenda and register now: https://ow.ly/f6lF50WKsPa

Join our esteemed chairs, Barbara Dehn, NP, and Anita Nelson, MD, and connect with fellow healthcare professionals for a dynamic, interactive, and evidence-based learning experience that extends beyond the annual visit. Why Attend WHAV 2025? ✅ Learn From Experts – Engage with world-renowned spea...

08/21/2025

Gain insights on interdisciplinary care in this interactive live symposium featuring real-world cases and expert guidance.

Register for the in-person event: https://ow.ly/Np6W50WJ3Ji
Sign up for lives broadcast: https://ow.ly/TgCs50WJ3Jj

Learn how to collaboratively manage thyroid eye disease (TED). This interactive, case-based CME symposium brings together endocrinologists and...

08/19/2025

Explore the evolving landscape of at our live satellite symposium! Join us for case-based insights into cutting-edge biomarkers, evolving guidelines, and emerging treatment strategies.

Register now: https://ow.ly/vSgO50WHKjF

Don't miss this satellite symposium, designed to equip you with the latest insights in precision medicine for IgA nephropathy (IgAN). Through...

08/15/2025

Can proteinuria serve as a validated surrogate endpoint in FSGS?

The PARASOL initiative—supported by the FDA and key kidney organizations—is working toward that goal.

By linking 2-year proteinuria levels with kidney failure risk, PARASOL aims to accelerate the approval of new FSGS therapies and create a data repository to support ongoing research.

Learn how this effort builds on DUPLEX and supports innovation in nephrology.

Full CME: https://ow.ly/Kh7q50WEyRO

Focal segmental glomerulosclerosis (FSGS) is a prominent cause of kidney failure globally, necessitating dialysis for patient survival as the...

08/07/2025

Migraine affects more women than men—by a factor of 3 to 4—and symptoms often vary by life stage, hormone status, and comorbidities.

At WHAV 2025, you’ll learn to:

- Recognize diagnostic clues specific to female patients
- Apply guideline-based acute and preventive strategies
- Address disparities in migraine care across diverse populations
- Personalize treatment plans based on goals, preferences, and life stage
- Improve shared decision-making around quality of life

Live in NYC | Sept 20

Register: https://ow.ly/wTXm50WBI3C